Medivir strengthens management team
This article was originally published in Scrip
Medivir, a research-based speciality pharma company focused on infectious diseases, has made several new appointments to its management team. Dr Maris Hartmanis joins the company as deputy CEO and COO, but will continue to work as CEO of Biophausia, which was recently acquired by Medivir. Professor Bertil Samuelsson, previously chief scientific officer, has been appointed chief scientific advisor focusing his efforts on the strategic development of Medivir's R&D. Dr Charlotte Edenius, previously vice-president of R&D, takes on the role of executive vice-president of R&D, and Dr Jens Kristensen has been appointed executive vice-president of the company's clinical unit. Dr Kristensen most recently served as vice-president of Karo Bio.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.